Aileen Healy has been focused on drug development for rare diseases for the past 10 years. At Pfizer, Aileen leads the External Science and Innovation efforts for the Rare Disease Research Unit, focusing on rare hematologic and neuromuscular diseases. Prior to joining Pfizer, Aileen was Vice President of Preclinical Development at Cydan, de-risking opportunities in lysosomal storage disease and hematology indications. Aileen began work in rare diseases at Seaside Therapeutics as Vice President of Research, where she focused on developing treatments to improve the course of neurodevelopmental disorders. Aileen has extensive experience in drug development leading preclinical research in multiple therapeutic areas at Momenta and Millennium Pharmaceuticals. She began her career as an Assistant Professor at Boston University School of Medicine, conducting biomedical research. Aileen holds patents and has published in peer-reviewed journals on a wide range of topics. Aileen received her PhD from Tufts University and postdoctoral training from the Massachusetts Institute of Technology.